1.30
0.00 (-0.04%)
| Previous Close | 1.30 |
| Open | 1.32 |
| Volume | 1,341,852 |
| Avg. Volume (3M) | 11,193,525 |
| Market Cap | 382,462,336 |
| Price / Sales | 2.44 |
| Price / Book | 0.760 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Profit Margin | -200.41% |
| Operating Margin (TTM) | -162.34% |
| Diluted EPS (TTM) | -1.58 |
| Quarterly Revenue Growth (YOY) | -32.80% |
| Total Debt/Equity (MRQ) | 132.42% |
| Current Ratio (MRQ) | 12.69 |
| Operating Cash Flow (TTM) | -232.97 M |
| Levered Free Cash Flow (TTM) | -190.76 M |
| Return on Assets (TTM) | -12.08% |
| Return on Equity (TTM) | -51.06% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Pacific Biosciences of Californ | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | -0.13 |
|
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 9.34% |
| % Held by Institutions | 85.09% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 2.50 (Stephens & Co., 92.38%) | Buy |
| Median | 2.00 (53.91%) | |
| Low | 1.50 (Goldman Sachs, 15.43%) | Hold |
| Average | 2.00 (53.91%) | |
| Total | 1 Buy, 2 Hold | |
| Avg. Price @ Call | 1.79 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 20 Feb 2025 | 2.00 (53.91%) | Hold | 1.64 |
| Goldman Sachs | 18 Feb 2025 | 1.50 (15.43%) | Hold | 1.87 |
| 23 Jan 2025 | 1.75 (34.67%) | Hold | 1.65 | |
| Stephens & Co. | 18 Feb 2025 | 2.50 (92.38%) | Buy | 1.87 |
| 14 Feb 2025 | 2.50 (92.38%) | Buy | 1.85 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |